Live feed12:30:00·872dPRReleasevia QuantisnowUpdated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term OutcomesByQuantisnow·Wall Street's wire, on your screen.REGN· Regeneron Pharmaceuticals Inc.Health Care